文献速递食管与纵隔外科

根治性放化疗与新辅助放化疗后手术治疗II至III期食管鳞状细胞癌的比较

Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-02-15

该回顾性队列研究纳入2000至2016年232例接受放化疗的II至III期中远端食管鳞癌患者,倾向性评分匹配后每组56例。与新辅助放化疗后手术相比,根治性放化疗组中位总生存期和无病生存期更短;手术与总生存期和无病生存期改善独立相关。作者认为在更好的病理完全缓解筛选工具出现前,手术应继续作为局部晚期食管鳞癌综合治疗的组成部分。

要点

  • 匹配后新辅助放化疗后手术组中位总生存期3.1年 vs 根治性放化疗组2.3年,中位无病生存期1.8年 vs 1.0年。
  • 手术与总生存期改善独立相关(HR 0.57,95%CI 0.34-0.97,P=.039)。
  • 手术与无病生存期改善独立相关(HR 0.51,95%CI 0.32-0.83,P=.007)。

核心结论

  • 新辅助放化疗后手术可能降低食管鳞癌患者局部复发并提高无病生存期和总生存期。
  • 在更好的病理完全缓解筛选工具出现前,手术应继续作为局部晚期食管鳞癌治疗的组成部分。

研究设计与样本

  • 回顾性队列研究,纳入2000至2016年II至III期中远端食管鳞癌且完成放化疗的患者232例。
  • 根治性放化疗组124例(53%),新辅助放化疗后手术组108例(47%)。
  • 采用倾向性评分匹配按1:1匹配协变量,匹配后每组56例。

主要发现

  • 新辅助放化疗后手术组中位总生存期3.1年 vs 根治性放化疗组2.3年。
  • 新辅助放化疗后手术组中位无病生存期1.8年 vs 根治性放化疗组1.0年。
  • 手术与总生存期改善独立相关(HR 0.57,95%CI 0.34-0.97,P=.039)。
  • 手术与无病生存期改善独立相关(HR 0.51,95%CI 0.32-0.83,P=.007)。
  • 新辅助放化疗后手术的使用随时间减少:2009年前为61%,2009年后为29%(P<.0001)。

临床怎么用

  • 作者认为,在更好的病理完全缓解筛选工具出现前,手术应继续作为局部晚期食管鳞癌治疗的组成部分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Definitive chemoradiotherapy (CRT) remains the most commonly used treatment for locally advanced esophageal squamous cell carcinoma (SCC), because of perceptions that esophagectomy offers an unclear survival advantage. We compare recurrence, overall survival (OS), and disease-free survival (DFS) in patients treated with definitive CRT or neoadjuvant CRT followed by surgery (trimodality). METHODS: This was a retrospective cohort study of patients with stage II and III SCC of the middle and distal esophagus in patients who completed CRT. Treatment groups were matched (1:1) on covariates using a propensity score-matching approach. The effect of trimodality treatment, compared with definitive CRT, on OS, DFS, and site-specific recurrence was evaluated as a time-dependent variable and analyzed using Cox regression with a gamma frailty term for matched units. RESULTS: We included 232 patients treated between 2000 and 2016: 124 (53%) with definitive CRT and 108 (47%) with trimodality. Trimodality was used less frequently over time (61% before 2009 and 29% after 2009; P < .0001). After matching, each group contained 56 patients. Median OS and DFS were 3.1 and 1.8 years for trimodality versus 2.3 and 1.0 years for CRT. Surgery was independently associated with improved OS (hazard ratio, 0.57; 95% confidence interval, 0.34-0.97; P = .039) and DFS (hazard ratio, 0.51; 95% confidence interval, 0.32-0.83; P = .007). CONCLUSIONS: CRT followed by surgery might decrease local recurrence and increase DFS and OS in patients with esophageal SCC. Until better tools to select patients with pathological complete response are available, surgery should remain an integral component of the treatment of locally advanced esophageal SCC.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Barbetta A, Hsu M, Tan KS, et al. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2018. PMID: 29548582. doi:10.1016/j.jtcvs.2018.01.086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。